| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Medicine, Erasmus University, Rotterdam, The Netherlands; and the Experimental Therapeutic Department Sandoz Ltd. Basel, Switzerland
Address all correspondence and requests for reprints to: Steven W. J. Lamberts, M. D., Department of Medicine, University Hospital Dijkzigt, 3015 GD Rotterdam, The Netherlands.
The acute GH inhibitory effects of 50 /g SMS 201–995, a somatostatin analog, and 2.5 mg bromocriptine were compared in 17 acromegalic patients. SMS 201–995 suppressed plasma GH levels after 2—6 h to 5 µg/liter or less in 10 of these 17 patients, while bromocriptine did the same in only 5 of them. There was much variation in the responsiveness to both drugs in these patients, but the GH–lowering effect of 50 ng SMS 2017– 995 was significantly greater than that of 2.5 mg bromocriptine. SMS 201–995 and bromocriptine togethersignificantly suppressed plasma GH levels in 2 of 3 acromegalic patients who were insensitive to both compounds when tested separately. We conclude that most acromegalic patients respond better toSMS 201–995, while a few patients are more sensitive to the GH–lowering effect of bromocriptine. In addition, the combination of SMS 201–995 and bromocriptine can be of value in a fewacromegalic patients who do not respond to either drug alone. (J Clin Endocrinol Metab 63:16,1986)
Received November 4, 1985.
This article has been cited by other articles:
 |
|
 |
|
  D. Ferone, F. Gatto, M. Arvigo, E. Resmini, M. Boschetti, C. Teti, D. Esposito, and F. Minuto The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology J. Mol. Endocrinol., May 1, 2009; 42(5): 361 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Miyoshi, F. Otsuka, H. Otani, K. Inagaki, J. Goto, M. Yamashita, T. Ogura, Y. Iwasaki, and H. Makino Involvement of bone morphogenetic protein-4 in GH regulation by octreotide and bromocriptine in rat pituitary GH3 cells J. Endocrinol., April 1, 2008; 197(1): 159 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Colao, M. Filippella, R. Pivonello, C. Di Somma, A. Faggiano, and G. Lombardi Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S57 - S63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-G. Ren, S. Kim, J. Taylor, J. Dong, J.-P. Moreau, M. D. Culler, and S. Melmed Suppression of Rat and Human Growth Hormone and Prolactin Secretion by a Novel Somatostatin/Dopaminergic Chimeric Ligand J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5414 - 5421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. U. Freda Somatostatin Analogs in Acromegaly J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3013 - 3018. [Full Text] [PDF]
|
|
|
|
|
|
R. Baldelli, A. Colao, P. Razzore, M.-L. Jaffrain-Rea, P. Marzullo, E. Ciccarelli, E. Ferretti, D. Ferone, D. Gaia, F. Camanni, et al. Two-Year Follow-Up of Acromegalic Patients Treated with Slow Release Lanreotide (30 mg) J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4099 - 4103. [Abstract] [Full Text]
|
|
|
|
|
|
S. Melmed, I. Jackson, D. Kleinberg, and A. Klibanski Current Treatment Guidelines for Acromegaly J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2646 - 2652. [Abstract] [Full Text]
|
|
|
|
|
|
A. Colao, D. Ferone, P. Marzullo, A. Di Sarno, G. Cerbone, F. Sarnacchiaro, S. Cirillo, B. Merola, and G. Lombardi Effect of Different Dopaminergic Agents in the Treatment of Acromegaly J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 518 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W.J. Lamberts, A.-J. van der Lely, W. W. de Herder, and L. J. Hofland Octreotide N. Engl. J. Med., January 25, 1996; 334(4): 246 - 254. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yamashita, M. Izumi, and S. Nagataki Acromegaly and Pituitary Carcinoma Ann Intern Med, December 15, 1992; 117(12): 1057 - 1058. [Abstract] [PDF]
|
|
|
|
 |
|
 M. L. Vance and A. G. Harris Long-term Treatment of 189 Acromegalic Patients With the Somatostatin Analog Octreotide: Results of the International Multicenter Acromegaly Study Group Arch Intern Med, August 1, 1991; 151(8): 1573 - 1578. [Abstract] [PDF]
|
|
|
|
|
|
K. Y. Ho, A. J. Weissberger, P. Marbach, and L. Lazarus Therapeutic Efficacy of the Somatostatin Analog SMS 201-995 (Octreotide) in Acromegaly: Effects of Dose and Frequency and Long-Term Safety Ann Intern Med, February 1, 1990; 112(3): 173 - 181. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
